A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

• Status: Recruiting
• Trial end date: 2024-04-01

Summary

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Pierre Fabre Medicament
• Collaborator: Merck KGaA, Darmstadt, Germany
• Treatments: Cetuximab; Fluorouracil; Irinotecan